Drawing for JUMRYRA

USPTO serial 79352033

JUMRYRA

Reviewed by CopyMark Law Group

Reg. 7178569Status 404
Filing date
Status date
Registration date
Oct 3, 2023
Examiner
COGAN, BRITTNEY LORRAINE
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with JUMRYRA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Maury M. Tepper, III

Maury M. Tepper, III Tepper & Eyster, PLLC3724 BENSON DRRALEIGH, NC 27609UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthmaSECTION 70 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Aug 13, 2026DENANOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED—
Aug 13, 2026DETHDEATH OF INTERNATIONAL REGISTRATION—
Jan 30, 2024FINVFINAL DECISION TRANSACTION PROCESSED BY IB—
Jan 9, 2024FICSFINAL DISPOSITION NOTICE SENT TO IB—
Jan 9, 2024FIMPFINAL DISPOSITION PROCESSED—
Jan 3, 2024FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Oct 3, 2023NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Oct 3, 2023R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jul 18, 2023NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jul 18, 2023PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jun 28, 2023NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jun 13, 2023PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Jun 6, 2023CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jun 5, 2023TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jun 5, 2023CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jun 5, 2023ALIEASSIGNED TO LIE—
Feb 17, 2023TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 6, 2023RFNTREFUSAL PROCESSED BY IB—
Jan 19, 2023RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Jan 19, 2023RFRRREFUSAL PROCESSED BY MPU—
Nov 8, 2022RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Nov 7, 2022CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Nov 7, 2022TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Nov 7, 2022ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
Nov 7, 2022ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Nov 7, 2022REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Nov 7, 2022COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Nov 7, 2022CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 3, 2022DOCKASSIGNED TO EXAMINER—
Oct 25, 2022MAFRAPPLICATION FILING RECEIPT MAILED—
Oct 21, 2022NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Oct 20, 2022LIMILIMITATION FROM ORIGINAL APPLICATION ENTERED—
Oct 6, 2022SDRCSN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB—

Frequently asked questions

Related guidance